Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.
J Comp Eff Res
; 10(5): 393-407, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33565893
Lay abstract The US FDA recently approved esketamine nasal spray plus an oral antidepressant (AD) as a new treatment for adults with treatment-resistant depression. We developed an Excel-based model to understand whether esketamine + oral AD treatment offers better value for the money spent, compared with treatment with oral AD alone. We find that the higher annual costs of esketamine + oral AD treatment are more than offset by the better clinical outcomes achieved with this treatment. Specifically, in a given year, more people treated with esketamine + oral AD versus oral AD alone achieved and remained in remission, and as a result, they incurred fewer other medical costs.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Depressão
/
Sprays Nasais
Tipo de estudo:
Clinical_trials
/
Health_economic_evaluation
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article